Biophytis Shares Gain After Detailed Data From Pivotal COVID-19 Treatment Study

  • Biophytis SA BPTS has released the full results from its phase 2-3 COVA study evaluating Sarconeos (BIO101) for COVID-19-related respiratory failure.
  • The study's objective was to investigate the efficacy and safety of Sarconeos (BIO101), 350 mg BID, in hospitalized COVID-19 patients with hypoxemia, at risk of respiratory failure requiring high flow oxygen or mechanical ventilation, and death. 
  • On respiratory failure or early death, post-hoc analyses show a significant reduction with Sarconeos (BIO101) in the risk of early death or respiratory failure at day 28 by 45% in the Intent-To-Treat (ITT) population and by 53% in the Per Protocol (PP) population.
  • In the primary analysis, Sarconeos reduced by 39% the risk of respiratory failure or early death at 28 days compared to the placebo.
  • On mortality follow-up over 90 days, the risk of death was reduced with Sarconeos by 43% in the ITT population and 70% in the PP population. 
  • Sarconeos (BIO101) has a good safety profile, with a lower proportion of patients with adverse events compared to placebo (57% vs. 64%), in particular, a lower frequency of serious, primarily respiratory, adverse events (25% vs. 31%).
  • The company aims to file for conditional marketing authorization (Europe) and emergency use authorization (U.S., Brazil) as soon as possible in 2023. 
  • Price Action: BPTS shares are up 20.3% at $0.71 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!